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Abstract (150/150 word max) 
 
The introduction of efficacious new hepatitis C virus (HCV) treatments galvanized the World 
Health Organization to define ambitious targets for eliminating HCV as a public health threat 
by 2030. Formidable obstacles to reaching this goal can best be overcome through a micro-
elimination approach, which entails pursuing elimination goals in discrete populations 
through multi-stakeholder initiatives that tailor interventions to the needs of these 
populations. Micro-elimination is less daunting, less complex, and less costly than full-scale, 
country-level initiatives to eliminate HCV, and can build momentum by producing small 
victories that inspire more ambitious efforts. The micro-elimination approach encourages 
stakeholders who are most knowledgeable about specific populations to engage with each 
other, and also promotes the uptake of new models of care. Examples of micro-elimination 
target populations include medical patients, people who inject drugs, migrants and 
prisoners, although candidate populations can be expected to vary greatly in different 
countries and sub-national areas.  
 
  
Introduction 
 
The introduction of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus 
(HCV) infection in 2013 is one of the greatest advances of the current biomedical era. 
Treatment with DAAs achieves sustained virologic response (SVR) rates of ≥95% after 8–12 
weeks of treatment for one of the leading causes of chronic liver disease and liver-related 
deaths worldwide. 1 2 3 The efficacy of the new DAA treatment regimens galvanized the 
World Health Organization (WHO) to adopt its first-ever Global Health Sector Strategy on 
Viral Hepatitis in 2016. The strategy defines ambitious time-bound targets for eliminating 
HCV as a public health threat by 2030. One key target is for countries worldwide to reduce 
new HCV cases by 80% and another is to reduce HCV-related deaths by 65% by 2030.1 
 
Scaling up DAA treatment is essential for achieving the HCV targets, but this constitutes an 
enormous public health challenge. A major obstacle is underdiagnosis: only 20% of people 
with HCV worldwide have been diagnosed.2 While approximately 71 million people were 
thought to be infected with HCV in 2015, only 1.76 million people received HCV treatment in 
2016.1 Three quarters of people with HCV live in low- and middle-income countries5, many 
of which lack the resources to stage major HCV testing and treatment campaigns. In January 
2018, the Polaris Observatory reported that only nine countries were on track to meet the 
2030 WHO HCV elimination targets: Australia, Egypt, France, Georgia, Germany, Iceland, 
Japan, the Netherlands, and Qatar.2 
 
 
What is the micro-elimination approach to eliminating HCV? 
 
In 2017, the European Association for the Study of the Liver’s International Liver Foundation 
suggested that stakeholders can best grapple with the complexity of the HCV elimination 
challenge by setting micro-elimination goals – “break[ing] down national elimination goals 
into smaller goals for individual population segments, for which treatment and prevention 
interventions can be delivered more quickly and efficiently using targeted methods.”1 The 
following review builds on this concept by distinguishing a micro-elimination approach from 
efforts to merely reduce HCV prevalence, incidence, and mortality in specific populations. 
Generally speaking, micro-elimination approaches should meet the following criteria, 
although these criteria may need to be adapted to different epidemiologic situations and 
geographic settings: 
 
1. There is a plan for how to tailor health resources and services to overcome known 
barriers and achieve high levels of HCV diagnosis and treatment in one or more 
clearly definable populations of interest within a specified timeframe. 
2. The plan sets forth achievable annual targets, basing these on mathematical 
modeling when relevant to determine the levels of diagnosis and treatment required 
to progress to the plan’s ultimate elimination targets. 
3. The plan is developed and implemented through a multi-stakeholder process, with 
essential participants including government officials, health service providers, and 
civil society representatives. 
4. Progress and outcomes are monitored and publicly reported using indicators 
selected at the outset of the process. 
 
There can be a great deal of variation in the geographic scope of micro-elimination efforts. In 
some cases, it might be logical to pursue micro-elimination in a specific population 
nationally, while in other cases there are reasons to work on a smaller scale, such as 
regionally or at the city level. An initiative employing a micro-elimination approach might 
focus on only one population, or it might focus on all of the populations affected by HCV 
within a designated geographic area. In cases in which comprehensive national HCV 
elimination efforts are proposed or underway, such as in Iceland (Box 1), it may be the case 
that these efforts encompass multiple micro-elimination approaches. For the sake of 
conceptual clarity, however, we propose that efforts to eliminate HCV in all populations at 
the national level not be considered micro-elimination, even when the country has a very 
small population. 
 
Activities targeting some of the smallest sub-populations of HCV-infected people, such as an 
initiative to cure HCV in all patients attending a single health clinic, would make welcome 
contributions to HCV elimination but might not actually embody the micro-elimination 
approach if the task at hand does not require a multi-stakeholder planning and 
implementation process. On the other hand, an effort to eliminate HCV in a population of 
the same size at a single prison would constitute micro-elimination if stakeholders engage in 
this undertaking in a way that embodies the aforementioned criteria. The micro-elimination 
approach particularly emphasizes choosing the interventions that are most relevant to the 
population of interest, tailoring these interventions in accordance with evidence about the 
population’s needs, and tracking how the interventions contribute to progress toward 
publicly agreed-upon elimination goals. Preferably, those goals would align with the global 
goals set by WHO.4 
 
While pursuing a micro-elimination strategy requires grouping people with HCV infection 
into different populations, some individuals are in reality members of more than one 
population. Hence, an HCV-infected migrant who injects drugs, for example, might be 
engaged in care through more than one micro-elimination pathway. At the same time, 
multiple pathways might be required to reach different subgroups within the same 
population. A micro-elimination program targeting people who inject drugs (PWID), for 
example, might need to use different types of service delivery models for PWID who are 
receiving opioid substitution therapy and those who are not, or for PWID who are 
incarcerated versus those in the community.   
 
HCV-infected children fall into many of the populations described in this article as potential 
micro-elimination targets, including aboriginal and indigenous communities, migrants, and 
PWID. It is important to consider the ways in which children and adults differ from each 
other in regard to their HCV prevention and treatment needs (Box 2). Women of 
childbearing age are another group that warrants special consideration across micro-
elimination initiatives in different populations. The estimated global number of women of 
childbearing age (aged 15–44 years) who have HCV viremia is 13.0 million1, with injecting 
drug use thought to account for increasing numbers of infected women and children in some 
settings in recent years.1 2 Children and women of childbearing age, generally speaking, may 
not be practical micro-elimination targets because both populations are so large and diverse 
that tailored interventions would still be needed for many different subpopulations. It is 
advisable for micro-elimination strategies targeting almost all populations to take into 
account whether the needs of children and women of childbearing age within those 
populations are being addressed. In some settings, HCV epidemic dynamics might argue in 
favor of developing micro-elimination initiatives specifically targeting populations such as 
children receiving inpatient hospital care or women of childbearing age in prisons, to name 
two of many possible examples. 
 
The micro-elimination approach is not meant to override medical and ethical standards 
widely endorsed by the global community of HCV stakeholders; it is instead offered to aid 
strategic decision-making in situations where the most appropriate use of resources is not 
already clear. Furthermore, as everyone holds the same human rights to health services, it is 
essential to provide a strong rationale for why some populations are being chosen over 
others for micro-elimination programs, along with a commitment to address the HCV-
related needs of those other populations in conjunction with pursuing micro-elimination. 
International human rights standards in fact call for governments that prioritize the 
allocation of limited health resources to specific populations to set targets for when those 
resources will reach everyone in need – a concept known as progressive realization.1 In 
other words, a health system cannot use a micro-elimination initiative targeting patients 
undergoing hemodialysis, for example, as an excuse to turn its back on HCV-infected PWID 
or migrants. National and subnational HCV elimination plans must take into account all HCV-
affected populations and must set goals and targets accordingly; the micro-elimination 
approach merely constitutes a method of focusing and organizing on-the-ground activities in 
order to take tangible steps toward the larger goal of eliminating HCV in the entire 
population.2 
 
An essential component of HCV elimination is reducing transmission by infected people who 
have not yet been treated or not responded to treatment. Prevention thus needs to remain 
a prominent element of national and subnational responses to HCV. There are large gaps in 
HCV prevention services in many low- and middle-income countries (LMIC) with high HCV 
prevalence. As a global micro-elimination agenda emerges, this agenda must not be 
permitted to draw attention and resources away from some of the most basic HCV 
prevention needs of LMIC. For example, there are unrealized opportunities to reduce 
nosocomial transmission of HCV in some LMIC.2 Further, many LMIC have yet to 
acknowledge the importance of PWID populations in their countries. As such there is a 
dearth of needle and syringe programs and opioid substitution therapy services.2 The global 
community of HCV stakeholders, including funders, should make it a priority to foster health 
system policies and interventions addressing HCV prevention. 
 
Why take a micro-elimination approach? 
 
The challenges associated with eliminating HCV encompass both logistic and political 
considerations: many health systems are not prepared to massively increase HCV 
prevention, testing and treatment activities, while many stakeholders who influence the 
allocation of financial and human resources are not convinced of the need to prioritize HCV 
or are unable to come to an agreement on how HCV elimination targets should be pursued. 
The micro-elimination approach can present many pathways for overcoming these issues. 
Micro-elimination is likely to strike stakeholders as less daunting, less complex, and less 
costly than full-scale country-level initiatives to comprehensively eliminate HCV. In the many 
countries that have not formally established the goal of HCV elimination, setting and 
achieving micro-elimination goals can serve as a step in this direction, with early successes 
inspiring more ambitious efforts.  
 
From a public health standpoint, a key feature of HCV is that its diverse transmission routes 
have resulted in the spread of the disease among a wide range of populations. The micro-
elimination approach encourages stakeholders who are the most knowledgeable about 
specific populations to engage with each other. Having the goal of eliminating HCV among all 
patients on hemodialysis nationally, for example, might foster collaboration among diverse 
stakeholders who can help drive progress, including different types of clinical specialists, 
various cadres of health-care workers, public health officials and patient groups. 
Furthermore, organizing around micro-elimination goals could create opportunities for 
cross-border collaboration, e.g., hemophilia patient groups working at a regional or global 
level might be asked by their in-country counterparts to help lobby governments to adopt 
micro-elimination targets. A micro-elimination approach could also encourage the uptake of 
new models of care, such as the co-location of services or shifting of HCV testing and 
treatment sites to different hospital departments or outside of hospital settings.2 3 4 5 6 
 
Micro-elimination approaches in populations at high risk of transmitting HCV can potentially 
contribute to “treatment as prevention”.2 The concept of treatment as prevention is to 
successfully treat an HCV-infected person who is at risk of passing the virus on to others and 
eliminate the possibility of further transmission, thereby achieving “prevention.” While 
there is not yet a real-world demonstration of the potency of treatment as prevention, 
modeling indicates that carrying out this strategy on a sufficiently large scale accelerates 
progression to population elimination, with especially notable gains seen when PWID are the 
focus in HCV epidemics driven by injecting drug use.2 3 In other words, if a large proportion 
of HCV-infected PWID in a specific geographic area undergo successful treatment and 
achieve SVR, this will result in a sharp drop in the number of HCV-infected people who have 
the potential to transmit the disease to others with whom they share injecting equipment.20 
The aim of treatment as prevention is to successfully treat enough people to reach a 
threshold where new infections are greatly reduced. Because of the potential to prevent 
further infections, many of which would incur the high costs of treating end-stage liver 
disease, models suggest that high levels of treatment combined with other preventive 
measures may prove cost effective, especially if indirect costs such as loss of earnings due to 
disability are considered.2 3 
 
While a micro-elimination approach is not required to take advantage of treatment as 
prevention, it presents the opportunity to comprehensively engage in processes that make 
treatment as prevention more likely to be successful, e.g., the involvement of a broad 
coalition of stakeholders and the careful tracking of changes in HCV incidence and 
prevalence. 
 
Which populations should be targeted for micro-elimination? 
 
Candidate populations for micro-elimination approaches can be expected to vary greatly in 
accordance with the epidemiology and health context of different countries and sub-
national areas. In this review, we discuss key features of 10 candidate populations. Other 
populations also warrant attention, and researchers and technical experts are encouraged to 
publish information about all potential micro-elimination populations in order to move this 
aspect of HCV elimination forward. Given that affected populations are not the same across 
all countries, the following subsections are arranged alphabetically to avoid the implication 
that some populations should be uniformly prioritised above others. 
 
Aboriginal and indigenous communities 
 
Some aboriginal and indigenous communities are disproportionately affected by HCV, 
including communities in Australia2, Canada and the United States. For example, the acute 
HCV infection rate for American Indian and Alaska Native (AI/AN) populations was 
approximately twofold higher than that of non-Hispanic whites in 2015, while the HCV-
associated mortality rate was threefold higher than that of non-Hispanic whites.2 Studies 
have indicated that HCV prevalence may be three to eight times higher in some Aboriginal 
Canadian populations than in non-Aboriginal Canadian populations.2 3 While there are 
limited data from Latin America, a Colombian study found 5.7% HCV antibody prevalence 
among Amerindians belonging to four ethnic groups.2 In contrast, overall HCV antibody 
prevalence in Columbia is estimated to be 1.1%.2 
 
Isolation, rural location, poverty, and communication barriers as well as cultural beliefs can 
all contribute to lack of testing and treatment uptake in aboriginal and indigenous 
populations.2 3 Studies in Australia and the United States have documented good outcomes 
for HCV testing and treatment programs targeting aboriginal and AI/AN populations,2 3 and 
the success of one US initiative led to the launch of the Cherokee Nation HCV elimination 
program in 2015.4 There appears to be little other research to guide the design of HCV 
elimination interventions for aboriginal and indigenous communities. 
 
Birth cohorts with high HCV prevalence 
 
In most countries, a group of people born in a specific span of years has a higher prevalence 
of HCV infection than the general population. This group is known as a “birth cohort.” This 
“cohort-effect” occurs due to changing infection modes. In some countries, for instance, 
many HCV infections are attributable to unsafe medical procedures that were largely 
eliminated when the danger was recognized and better infection control measures were put 
into place.2 The span of cohorts affected varies across countries.2 3 4 While in the United 
States people born from 1945 to 1965 are at higher risk26, the Mexican cohort is older37,  the 
Czech Republic’s is younger36, and Poland appears to have no correlation between age and 
HCV prevalence.2 The possible existence of an at-risk birth cohort thus needs to be 
investigated on a country-by-country basis. In countries where there are birth cohorts with 
high HCV prevalence, a key advantage of birth-cohort testing is that it removes potential 
stigma from testing, as everyone within the age group is tested regardless of behavior, 
removing the perception of blame.2 A review examining the cost–effectiveness of 
interventions, which included eight studies evaluating birth cohorts in four countries (all 
with known high-risk birth cohorts approximately 50 years of age and older), found that in 
all instances, birth-cohort testing was cost effective when compared to either the status quo 
or even risk-based testing.40 Similar results were found in Switzerland where far fewer 
people needed to be screened in specific cohorts to find one new HCV infection as compared 
to the general population.38 Despite this, global stakeholders have been slow to add birth-
cohort analysis to their recommendations, and the first-ever WHO Global Health Sector 
Strategy on Hepatitis 2016–21 fails to make any mention of it.4 One-time HCV testing of 
patients in high-risk cohorts has been recommended for both the United States and 
European countries,2 and may be found useful in countries with a clearly identifiable at-risk 
birth cohort. However, defining this cohort requires population-based seroprevalence data, 
and not many countries have conducted the large and expensive national surveys that are 
required to obtain these data.   
 
Children of HCV-infected mothers 
 
Mother-to-child transmission of HCV is the primary mode of infection for children. According 
to a 2014 systematic review, there is a 5.8% risk of mother-to-child HCV transmission among 
HIV-negative women, and a 10.8% risk among HIV-positive women.2 Although this 
represents a low transmission risk per individual case, mother-to-child transmission still may 
add considerably to the burden of HCV disease. Unfortunately, there are several barriers to 
both identification and treatment in this group. Although RNA testing is accurate as early as 
two months of age, antibody testing of infants less than 15 months of age is complicated by 
maternal antibodies.2 3 A prospective study in Tennessee found that more than half of the 
infants of infected mothers left pediatric care prior to the 18-month appointment at which 
they would be tested for HCV2, indicating that loss to follow-up is potentially a major 
challenge in this population. Furthermore, although DAAs have been approved in children 
aged 12–17 years, studies for younger children have not yet been completed.44 Because of 
these limitations, infected children are likely to remain infected for an extended time, 
making it all the more important that they receive regular liver function tests and HCV RNA 
quantification until they reach an age at which they are eligible for treatment with DAAs.44 
 
Regarding the issue of how more HCV-infected children can be diagnosed, current World 
Health Organization guidelines recommend against routinely testing pregnant women in the 
general population for HCV2, reflecting the lack of evidence of this approach being cost-
effective.2 In the context of developing micro-elimination strategies targeting children in 
specific settings, it may be advisable to consider the possible role of universal screening of 
pregnant women in those settings. This is a rapidly evolving area of research, and new 
evidence may influence changes in guidelines and best practices.  
 
Hemodialysis recipients 
 
The transmission of HCV to hemodialysis patients has declined over the years due to better 
screening of blood products, improved dialysis procedures, and less need for blood 
transfusion with the availability of erythropoiesis—stimulating agents. Nonetheless, HCV 
prevalence remains far higher in people receiving hemodialysis than in the general 
population.2 3 4 In lower-income countries, both transfusion of contaminated blood products 
and hand-borne nosocomial transmission continue to be major infection pathways13, but for 
higher-income countries the latter is currently the key pathway.2 Interferon-based therapies 
are not well tolerated by hemodialysis patients, as reflected in treatment rates of 1–4% in 
high-income countries.51 2 3 DAAs, however, are proving to be well tolerated and effective in 
this population.49 2 3 Furthermore, because patients with chronic kidney disease and HCV 
infection may lose kidney function at an accelerated rate compared to HCV-negative 
patients, and because HCV can cause complications in post-kidney-transplant patients, it is 
often recommended that patients receive treatment prior to transplantation53 2 3, unless an 
HCV-infected graft is rapidly available and HCV treatment can be provided following 
transplantation. Since acute HCV infection is frequently asymptomatic, regular screening is 
advised from the start of maintenance hemodialysis.49 2 Spontaneous clearance is rare 
among hemodialysis patients, so treatment should be provided as soon as possible.51 
Thorough training and strict adherence to infection control protocols by staff are necessary 
to prevent future infections.48 58 There is a need for rigorous screening to ensure that no 
new recipients of hemodialysis are infected with HCV, since such cases would allow for the 
reintroduction of HCV in hemodialysis units where progress had been made toward HCV 
elimination. The widespread treatment of HCV in people receiving hemodialysis will likely 
achieve the “treatment as prevention” outcome of reducing the incidence of transmission in 
hemodialysis units when paired with appropriate prevention measures.2 
 
HIV/HCV-coinfected people 
 
It is estimated that worldwide, at least 2.3 million people are coinfected with HIV/HCV.2 
People come to be coinfected with HIV/HCV via various pathways, often related to ongoing 
risk factors; common modes of transmission include the use of unsterile injecting drug 
equipment and sexual transmission between men. Reinfection is a particular challenge in 
men who have sex with men (MSM), with a reinfection rate of 25% observed in a large 
Western European cohort after two years of follow-up.2 Regular testing is therefore 
recommended. Since HIV therapy needs to be given lifelong, and follow-up visits are 
regularly scheduled, such patients are readily available for testing and, if necessary, 
treatment for HCV. Furthermore, two studies from the Netherlands and Switzerland have 
shown that high rates of DAA treatment uptake by their HIV/HCV-coinfected cohorts 
reduced new acute HCV infections in MSM by around 50%3 4, leading to the possibility of 
treatment as prevention and making elimination far more feasible. Coinfection with HIV 
does not impact the effectiveness of HCV treatment: equally high SVR rates can be found in 
HIV/HCV-coinfected patients as in HCV-monoinfected patients.3, 4 
 
Migrants from high-prevalence countries 
 
Due to risk factors such as HCV prevalence in their country of origin, countries visited during 
their journey as migrants, and the conditions they experienced during migration, immigrants 
and refugees (collectively referred to in this article as migrants) are at elevated risk of being 
infected with HCV as well as having other health problems. Migrants often remain 
unidentified and thus untreated. According to a 2015 review, anti-HCV prevalence among 
migrants was 1.9% overall, with higher rates associated with region of origin, particularly 
Eastern Europe, Asia, and Sub-Saharan Africa.2 Factors that often limit HCV testing in 
migrant populations include lack of knowledge about where and how to get tested, concern 
for how a positive result might affect the host country’s acceptance, lack of primary health 
care, and providers’ possible reluctance to test for chronic conditions in patients they may 
never see again.3 Furthermore, because they may not belong to populations that the host 
country considers to be at high risk, current screening practices may allow migrants to fall 
through the cracks and remain untested.66 3 Although migration status in and of itself is not 
an indicator for HCV, region of origin is; migrants from countries with a high and moderate 
prevalence of HCV are at greater risk of infection.68 There have been some efforts to reach 
this marginalized population. An HCV screening program started in southern Italy in 20122 
not only tested undocumented immigrants and low-income refugees, but offered treatment 
and linkage to care, showing that it was possible to identify and retain migrant patients 
throughout the testing and treatment process.67 Another Italian study, based in Palermo, 
retained 87% of patients and achieved SVR in 100% of the treated patients.2 A successful 
micro-intervention strategy targeting migrants from high-prevalence countries must include 
provision for screening and linkage to care, as well as cultural mediators for translation and 
explanation of the importance of screening and treatment.69 
 
People who inject drugs 
 
Globally, PWID account for 8% of all chronic HCV infections and 23% of new infections5, 
making them a large and growing segment of the HCV burden. They are a particularly 
important population to treat, both because of their high prevalence and the dynamic 
spread of infection among the larger population.2 This situation makes it likely that 
“treatment as prevention” will need to play a key role in eliminating HCV in PWID. 
Unfortunately, because injection drug use is often stigmatized and even illegal, PWID are 
less likely to seek out or accept medical help. Health systems, often government provided, 
frequently impose barriers relating to a lack of housing or a permanent address; are 
inflexible with locations and appointment times; and are physically distant from the person, 
with travel costs being a disproportionate burden. Some countries also do not provide 
antiviral treatment to current drug users. There is, however, extensive evidence that PWID 
can be effectively targeted and treated. 20 2 3 4 For example, studies in Scotland and Iceland 
found that it was possible to cure active drug users of HCV;2 3 nurse-led models of care have 
proved efficacious in improving access to care and successful treatment outcomes2 3, and a 
community-based public health facility in Sydney, Australia found that PWID can be 
successfully treated for HCV using an integrated primary health-care model. It also 
demonstrated the feasibility of scaling up DAA therapy in high-risk PWID populations, with 
potential individual and population-level public health benefits.2 
 
PWID populations need specific care pathways for HCV diagnosis and treatment, and these 
pathways should be based around facilities and services that they are already accessing. 
Because many PWID already utilize opioid substitution therapy as well as needle and syringe 
programs, the facilities and locations where these interventions and treatments take place 
are ideal for new HCV diagnosis and treatment initiatives. There are also models for 
engaging PWID who do not seek out these services. In Iceland, for example, the national HCV 
elimination program has targeted homeless shelters as part of its extensive outreach 
measures.2 HCV treatment should be provided to PWID as part of the comprehensive 
package of interventions recommended by WHO, UNAIDS and the United Nations Office on 
Drugs and Crime for HIV prevention, treatment and care for injecting drug users. This 
landmark guidance document calls for viral hepatitis prevention, vaccination, diagnosis and 
treatment along with key harm reduction services such as opioid substitution therapy and 
needle and syringe programs.3 
 
Health systems with a wide range of epidemiologic scenarios can benefit from targeting 
PWID for micro-elimination. It is believed that with expanded screening for HCV, especially 
among PWID, Iceland could reach the WHO targets by 2020, becoming one of the first 
countries to achieve HCV elimination.2 The government of Iceland committed to a 
comprehensive elimination program despite the fact that the country’s estimated HCV-
infected population in 2014 was only 1100.80 At the other end of the spectrum, Georgia, a 
country with one of the highest global burdens of HCV, has developed an elimination pilot 
program that includes intensified HCV detection efforts and increased harm reduction 
services for PWID.3 4 In the UK, the Tayside region of Scotland is being used as a test bed of 
regional micro-elimination, using an integrated combination of pathways to target all groups 
infected with HCV, especially focusing on treatment of PWID in needle exchange programs, 
to prove the concept of “treatment as prevention.” The complementary pathways to needle 
exchange include: conventional nurse-led outreach programs, pharmacist-led treatment of 
patients on opioid substitution therapy in community pharmacies, treatment in prisons, and 
treatment by embedded hepatitis specialist nurses in addiction treatment centers. All of 
these services will deliver the volume of treatment modeled to reduce prevalence below 
10% and incidence to below 1% over 3 years, thereby achieving elimination.3 
 
People with hemophilia and other inherited blood disorders 
 
Prior to 1990, transfusion of blood and blood products was the primary vector for 
transmission of HCV infection in people with hemophilia and other hereditary blood 
disorders, such as Von Willebrand disease and thalassemia. 3 The burden of HCV disease 
remains high in this population, even in high-income countries where there have been 
almost no new cases of HCV in patients with hemophilia in recent years. Those with 
hemophilia have much higher mortality due to chronic HCV than the general public.86 In the 
past, these patients often declined HCV treatment due to side-effects, but DAAs are much 
better tolerated and are highly effective in this population. A Japanese study investigated 
the safety and efficacy of DAAs among 27 individuals with hemophilia and HCV/HIV 
coinfection. All study patients achieved SVR after receiving interferon-free DAA therapy.3 
Walsh et al. found similar results in a study that enrolled individuals with chronic HCV and 
inherited blood disorders (hemophilia and Von Willebrand disease) in the United States.3 
Patients with thalassemia have also responded well to DAA treatment, with high SVR rates 
and few side-effects, even those who had not responded to previous interferon treatment 
and were considered difficult to treat.3 4 These studies suggest that individuals with inherited 
blood disorders may safely and successfully be treated for HCV with DAA therapy.88 Ireland’s 
elimination of HCV in patients with hemophilia3 (Box 3) and Slovenia’s in patients with all 
congenital bleeding disorders4 suggest that the lack of new infections and effectiveness of 
DAA treatment make micro-elimination in these groups of patients highly achievable. 
 
Prisoners 
 
Prisoners in most countries have a higher prevalence of HCV than the general population, 
but their access to treatment is very limited. 2 4 Although this high prevalence is in part due 
to conditions and experience prior to incarceration, with drug use, tattooing, and sexual 
activity being high-risk factors, once in prison, stresses including overcrowding and violence 
can cause inmates to begin or continue unsafe activities, resulting in a 30% estimated rate of 
new infections annually.93 Barriers to treatment include lack of testing, social stigma, and 
lack of availability of treatment options. HCV interventions, including treatment, can be 
delivered safely and effectively in prison settings, and should be an essential component of 
any national elimination strategy.4 5 Treatment within prisons has been shown to be cost 
effective in Scotland, even at DAA costs that are now historical.4 
 
A rapid DAA scale-up program initiated at a correctional facility in Cairns, Australia as part of 
a larger elimination strategy resulted in a fall in the prevalence of HCV viremia within the 
prison from approximately 12% to <1% over a 22-month period,  thereby effectively 
achieving HCV micro-elimination in this institution.4 Six reinfections were seen in the 
population studied, which underscores that incident cases of HCV will continue to occur 
unless serious efforts are made to improve harm reduction services in prisons.4 5 Nurse-led 
and specialist-supported models of care in Australian correctional facilities have been 
demonstrably effective in increasing treatment uptake among inmates with chronic HCV, 
with treatment responses in excess of 95% in some facilities.4 5 A study in Spain reported 
similar results, with a >99% adherence rate and a prevalence drop from 9.9% to .5% over the 
year it ran. All treated inmates achieved SVR after 8 or 12 weeks of treatment.4 Notably, this 
study also created a sustainable model for continuance: even after its completion, all new 
prisoners are screened and offered treatment.4 Rapid HCV testing and DAA treatment can 
also feasibly be delivered in transient jail populations, where inmates are often detained for 
fairly short or unpredictable periods of time, as observed by two studies conducted in the 
United States.95 5 In many countries, however, it is common for remand prisoners to be 
incarcerated for one week or less. Initiatives that target remand prisoners for HCV testing 
and treatment should have a strong linkage-to-care component with mechanisms for 
transferring care from the prison setting to the community setting upon release. 
 
Transplant recipients 
 
HCV infection increases mortality and graft loss in transplant recipients53 55 4,making them an 
important target group for a micro-elimination approach. In the past, HCV treatment post-
transplant was fraught with poor tolerance and was often unsuccessful. New DAA 
treatments have proven to be both safe and effective, and all transplant recipients who are 
viremic for HCV should be offered treatment before or after transplant.58 Therefore, the 
question in transplant recipients is less a matter of whether to treat HCV but when to do so. 
The majority of transplant recipients should be treated prior to surgery, but in a small subset 
of patients whose liver disease is so advanced that pre-transplant DAA therapy is either 
unsafe or ineffective, treatment should be delayed until after surgery.4 There are 
increasingly calls to consider using HCV-positive organs in HCV-negative recipients4 5, but this 
practice should be implemented only in the context of timely access to DAA therapy.   
 
Conclusion 
 
The micro-elimination approach discussed in this article has the potential to catalyze 
progress against HCV in a diverse range of epidemiologic settings. Stakeholders pursuing 
HCV elimination targets in countries worldwide should work together to further develop a 
micro-elimination agenda that will enhance these efforts. Such an agenda should call for 
rigorous research including social science research to document the outcomes of micro-
elimination initiatives. The monitoring of micro-elimination outcomes should incorporate 
key indicators of progress toward the WHO HCV elimination targets. WHO’s proposed viral 
hepatitis monitoring framework contains several indicators that are relevant for HCV micro-
elimination initiatives, including the following: (1) prevalence of HCV infection; (2) people 
living with HCV diagnosed; (3) treatment initiation; (4) cure; and (5) deaths from 
hepatocellular carcinoma, cirrhosis and liver diseases attributable to HCV.4 It is advisable to 
draw from the WHO indicators as much as possible in developing monitoring frameworks for 
micro-elimintation initiatives, as this will facilitate comparisons of outcomes and will allow 
for the aggregation of data across different settings. 
 
Research and stakeholder consultation are needed to develop decision-making tools for 
health systems that are exploring how to make the most strategic use of the micro-
elimination approach. A number of candidate micro-elimination populations are relatively 
easy to reach because they are already patients in care, e.g., for kidney disease, HIV or 
opioid substitution therapy. However, these populations do not necessarily include the 
largest numbers of HCV-infected people or the ones at greatest risk of transmitting the 
disease to others. A much greater expenditure of resources may be required to reach HCV-
infected people who are not already in care – but the return on the investment could 
potentially be greater strides toward elimination. Navigating decisions of this nature will 
require a much better evidence base than what is currently available. The publication of 
real–world operational research findings will greatly advance the micro-elimination agenda 
in the coming years, and will aid stakeholders in combining different micro-elimination 
models to achieve full-scale elimination and reach the 2030 HCV elimination targets. 
 
 
 
 
BOX 1 – What about MACRO-elimination? 
 
While the micro-elimination approach may be appealing to countries that are not yet 
prepared to fully implement national HCV elimination plans, it also speaks to the needs of 
countries pursuing full-scale elimination in that it emphases the importance of providing 
tailored services to reach specific populations whose engagement will be essential for 
achieving elimination. Although the launch of Iceland’s national HCV elimination program 
predates the introduction of the micro-elimination concept, it provides an instructive 
example of how the micro-elimination approach can enhance broader initiatives. 
 
A small nation of 340,000 people, all covered by national health insurance, Iceland had an 
estimated viraemic HCV population of 1,100 in 2014, with most cases resulting from 
injecting drug use. In 2015, Gilead Sciences and the relevant Icelandic parties came to an 
agreement that Gilead would provide DAAs to all of these patients and Iceland would 
provide the organization, diagnostic tests, and other related services required for the 
nationwide elimination campaign. An observational study would provide 36 months of 
treatment followed by 15 years of long-term follow-up observation. 
 
The idea is that by treating all patients in Iceland within a short timeframe and also providing 
other harm-reduction measures such as needle exchange services and opioid substitution 
therapy, there would consequently be fewer new infections, allowing for total elimination of 
the disease and proving the concept of “treatment as prevention.” All patients are offered 
testing and treatment regardless of whether they agree to participate in the study’s research 
arm. Active outreach and travel assistance are offered to encourage patients to take 
advantage of the program. The majority of patients were treated in the first two years, with 
the third year being devoted to new diagnoses and catching those cases that fell through the 
cracks, including relapses and reinfections. Long-term monitoring will track the incidence of 
domestic transmission as well as any long-term complications. It is expected that this 
aggressive, multi-pronged initiative will result in Iceland eliminating HCV well ahead of the 
WHO timeline as well as providing evidence that will aid other countries pursuing 
elimination goals.80 In the first 15 months of the program, 554 people with HCV were 
evaluated, of whom 94% initiated treatment. Viremic HCV prevalence among PWID dropped 
from 43% at baseline to 12% in 2017, a 72% reduction.4 
 
 
BOX 2 – Children and HCV 
 
Estimates of prevalence of HCV in children and adolescents range from .05%–.36% in high-
income countries to 1.8%–5.8% in some heavily affected low-income countries, but it is likely 
that these data severely underestimate actual prevalence.4 There are notable differences in 
how HCV manifests in children and adults, including progression of liver damage, clearance 
rates, treatment options, and length of potential chronic infection.4 Most infection in 
children is due to vertical transmission, but injecting drug use is an increasingly common 
infection route, especially for adolescents.4 Liver disease in children with chronic HCV is 
usually minor and there is often little evidence of progression.4 Although progression from 
fibrosis to cirrhosis is rare, occurring in approximately 2–3% of cases, fibrosis does progress: 
nearly a third of the 44 children with multiple liver biopsies (6 years apart on average) in the 
PEDS-C trial had increased severity of fibrosis, and the proportion with cirrhosis or bridging 
fibrosis increased from 11% to 20%.113 Spontaneous clearance rates are slightly higher for 
children than adults, mostly among children infected via vertical transmission, who have a 
25–40% chance of spontaneous viral clearance.43 Treatment for children with HCV is 
significantly behind that of their adult counterparts. Only in early 2017 were the first DAA 
treatments approved for adolescents (aged 12–17 years), and although studies on younger 
children are underway, currently the only treatments available for them are interferon-
based, which tend to be less effective and more toxic.5 112 Because of the side-effects of 
interferon-based treatments and the generally slow progression of liver disease in children, 
as well as the expectation of increasing availability of DAAs for children, treatment is not 
currently advised for children under 12 years in most cases.5 112 
 
BOX 3 – Eliminating HCV in people with hemophilia: the Irish experience 
 
Ireland implemented a strategy with elements of the micro-elimination approach in its 
elimination of HCV in people with hemophilia. In 1999–2001, Ireland held a tribunal 
inquiring into HCV and HIV in hemophiliacs and others who were infected via blood and 
blood products provided by the State. Its findings led the tribunal to call for the creation of a 
coordinating committee focusing on the care and treatment of patients with hemophilia, as 
well as for better communication among doctors caring for patients with hemophilia.4 In 
response, stakeholders formed the National Haemophilia Council, an advisory board 
consisting of a wide range of public health officials, advocacy groups, and medical 
professionals. When DAAs became available, the National Haemophilia Council and other 
groups advocated strongly for them to be offered to patients with hemophilia. The 
Department of Health consequently assured the Council that all State-infected patients 
would receive treatment beginning in mid-2015. This goal was met, and at the end of 2016 it 
was announced that hepatitis C had been eliminated among patients with hemophilia in 
Ireland.4 Although Ireland was successful, a true micro-elimination approach would include 
more specific quantitative goals and more detailed reporting of plans, progress and 
outcomes in order to make the process fully transparent. A notable lesson to take away from 
the Irish experience is that a history of effective multi-stakeholder collaboration in response 
to the health needs of some HCV-affected populations may provide a good foundation for a 
micro-elimination initiative. Ireland now has a hepatitis elimination plan for the country, 
with 2026 as the target year.4 The program is supported by a Clinical Advisory Group made 
up of health care professionals involved in the delivery of care to patients with HCV across a 
number of disciplines. 
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